NPJ vaccines · 2022
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buoninfante Alessandra, Andeweg Arno, Baker Alexander T, Borad Mitesh, Crawford Nigel, Dogné Jean-Michel, Garcia-Azorin David, Greinacher Andreas, Helfand Rita, Hviid Anders, Kochanek Stefan, López-Fauqued Marta, Nazy Ishac, Padmanabhan Anand, Pavord Sue, Prieto-Alhambra Daniel, Tran Huyen, Wandel Liminga Ulla, Cavaleri Marco
Аннотация
Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been demonstrated in clinical trials and next by their real world use through the course of the ongoing COVID-19 pandemic. However, very rare adverse events have been detected post-authorization in certain parts of the world. This meeting report summarizes an EMA workshop’s discussion on the epidemiology, clinical presentation and biology of thrombosis with thrombocytopenia syndrome after adenovirus vector COVID-19 vaccination. General agreement was reached by international regulators, scientists and developers on the steps needed to fill the gaps in the characterization of this new syndrome. In particular, actions should be taken to improve the post-vaccination surveillance activities in low and middle income countries and investigate potential genetic predisposition factors.